Completely humanized antibody targeting CD123 and application thereof

The invention belongs to the technical field of cellular immune engineering, and particularly relates to a fully human CD123 targeting antigen binding fragment and a single-chain antibody and application thereof. The sequence of the single-chain antibody provided by the invention completely comes fr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CHEN YUNFAN, ZHANG CHANGJIANG, LIU TONGCAN, XU YANMIN, GAO SHIJING, ZHAO WENXU, YAO RUINA, HUANG YUKANG
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention belongs to the technical field of cellular immune engineering, and particularly relates to a fully human CD123 targeting antigen binding fragment and a single-chain antibody and application thereof. The sequence of the single-chain antibody provided by the invention completely comes from a human antibody gene pool, compared with a mouse antibody, a chimeric antibody and a humanized antibody, the immunogenicity of the single-chain antibody is greatly reduced, and the safety can be ensured to the maximum extent in clinical application. 本发明属于细胞免疫工程技术领域，具体涉及一种全人源的靶向CD123的抗原结合片段和单链抗体及其应用。本发明提供的单链抗体序列完全来自于人类抗体基因库，与鼠源抗体、嵌合抗体、人源化抗体相较，其免疫原性大大降低，在临床应用上能够最大限度保证安全性。